Analyst Price Targets — IMUX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 12:51 pm | Boobalan Pachaiyappan | Roth Capital | $19.00 | $12.54 | TheFly | Immunic price target lowered to $19 from $26 at Roth Capital |
| April 30, 2026 10:05 am | Matthew Caufield | H.C. Wainwright | $22.00 | $10.03 | TheFly | Immunic price target adjusted to $22 from $5 at H.C. Wainwright |
| April 16, 2026 8:19 pm | — | Stifel Nicolaus | $2.50 | $1.00 | TheFly | Immunic initiated with a Buy at Stifel |
| October 21, 2022 3:14 pm | Market Perform | Leerink Partners | $5.00 | $2.09 | Benzinga | Analyst Downgrades Immunic After Lack of Details Drive Uncertainty |
Latest News for IMUX
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A.
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Prediction market traders are pricing a 78% chance that SpaceX closes its first day of trading above $2 trillion, a valuation that would rank it among the...
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to…
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood – NEW YORK, May 28, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMUX.
U.S. House Trading
No House trades found for IMUX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.